Short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after treatment; topical corticosteroids · people with traumatic hyphema
It is very uncertain whether systemic or topical corticosteroids changes short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after… compared with placebo or control treatment (very low certainty).
1 finding from 1 review
Final visual acuity between 20/20 and 20/25 at end of treatment; topical corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in final visual acuity between 20/20 and 20/25 at end of treatment;… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Time to resolution of primary hemorrhage · people with traumatic hyphema
2 findings from 1 review
Risk of secondary hemorrhage; topical corticosteroids · people with traumatic hyphema
It is very uncertain whether systemic or topical corticosteroids changes risk of secondary hemorrhage; topical corticosteroids compared with placebo or control treatment (very low certainty).
1 finding from 1 review
Short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Final visual acuity between 20/20 and 20/40 at end of treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in final visual acuity between 20/20 and 20/40 at end of treatment;… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Risk of secondary hemorrhage; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids may leads to lower risk of secondary hemorrhage; oral corticosteroids compared with placebo or control treatment (low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol · adults with eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events at · people with eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (16 weeks + 4 weeks acute phase) · children and adults with mild to severe eczema
It is very uncertain whether weekend therapy changes systemic adverse events: abnormal cortisol; end of treatment (16… compared with no topical corticosteroid (very low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
1 finding from 1 review